Management and care of the newly diagnosed patient with cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 4, Issue 6, 1998, Pages 311-318

  Varlotta, Laurie ^a  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; CHILD; CYSTIC FIBROSIS; DRUG COMBINATION; FEMALE; HUMAN; INFANT; LIFE EXPECTANCY; LUNG; LUNG FUNCTION TEST; MALE; METHODOLOGY; MICROBIOLOGY; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; LIFE EXPECTANCY; LUNG; MALE; PNEUMONIA, BACTERIAL; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032195198     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199811000-00001     Document Type: Article

References (43)

1. FitzSimmons SC: The changing epidemiology of cystic fibrosis. J Pediatr 1993, 122:1-8.
2. Cystic Fibrosis Foundation: National cystic fibrosis patient registry: 1996 Annual Data Report. Bethesda: Cystic Fibrosis Foundation; 1997.
3. Collins FS, Cystic fibrosis: molecular biology and therapeutic implications. Science 1992, 256:774-779.
4. Ramsey B: Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996, 335:179-188.
5. Davis PB, Drumm M, Konstan MW: Cystic fibrosis. Am J Respir Crit Care Med 1996, 154:1229-1256.
6. Quinton PM: Cystic fibrosis: a disease of electrolyte transport. FASEB J 1990, 4:2709-2717.
7. Varlotta L, Schidlow DV: CF lung disease: your role in therapy. J Respir Dis 1997, 18:119-126. This is a review of the clinical features, mechanism, course of the lung disease, and the goals of therapy of CF. Private practitioners and the multidisciplinary team at the CF center should work together to achieve the best possible outcomes.
8. Esterley JR, Oppenheimer EH: Cystic fibrosis of the pancreas: structural changes in peripheral airways. Thorax 1968, 23:670-675.
9. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
10. Konstan MW, Berger M: Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997, 24:137-142. New research has demonstrated that the inflammatory process plays a major role in the lung disease in CF. This is a review of the inflammatory process in the airway in CF.
11. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R: The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995, 20:63-70.
12. Kerem E: Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol 1996, 22:387-395.
13. Cystic Fibrosis Foundation: Cystic Fibrosis Foundation Guidelines. Bethesda: Cystic Fibrosis Foundation; 1996.
14. Stern RC: The diagnosis of cystic fibrosis. N Engl J Med 1997, 336:487-491.
15. Consensus Conferences: Concepts In Care. Cystic Fibrosis Foundation: The Diagnosis of Cystic Fibrosis: Consensus Statement. Bethesda: Cystic Fibrosis Foundation; 1996: VII(I):1-15.
16. Newborn Screening lor cystic fibrosis: a paradigm for public health genetics policy development. MMWR Morbid Mortal Wkly Rep 1997, 46:1-24. This is a booklet of the recommendations and report of the workshop discussing newborn screening in CF. A background in newborn screening, benefits and risks of screening, and laboratory issues are discussed at length. Overall recommendations are provided.
17. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns WT, et al.: Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med 1997, 337:963-969.
18. The Cystic Fibrosis Foundation Center Committee, Guidelines Subcommittee: Cystic Fibrosis Foundation guidelines for patient services, evaluation, and monitoring in cystic fibrosis centers. Am J Dis Child 1990, 144:1311-1312.
19. Connett G, Spencer D, Desai M, Weller P: The outcome of early and late referral among children attending a regional CF clinic in the West Midlands of England. Isr J Med Sci 1996, 32(suppl):S270.
20. Jedlicka-Kohler I, Gotz M, Eichler I: Parents' recollection of the initial communication of the diagnosis of cystic fibrosis. Pediatrics 1996, 97:204-209.
21. Schechter MS, Margolis PA: Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr 1998, 132:260-264.
22. Wall MA, LaGesse PC, Istvan JA: The "worth" of routine spirometry in a cystic fibrosis clinic. Pediatr Pulmonol 1998; 25:231-237. History alone does not always detect deterioration in some patients with CF. Spirometry is a justifiable part of all clinic visits for patients with CF to detect declines in pulmonary status.
23. Clayton RG, Diaz CE, Bashir NS, Panitch HB, Schidlow DV, Allen JL: Pulmonary function in hospitalized infants and toddlers with cystic fibrosis. J Pediatr 1998, 132:405-408.
24. Tepper RS: Assessment of the respiratory status of infants and toddlers with cystic fibrosis. J Pediatr 1998, 132:380-381.
25. Varlotta L, Schidlow DV: CF lung disease: choosing an antibiotic regimen. J Respir Dis 1997, 18:258-267. An update on the microbiology associated with CF lung disease and the different antibiotics used in CF lung disease.
26. Varlotta L, Schidlow DV: CF lung disease: managing airway obstruction. J Respir Dis 1997, 18:414-422. Airway obstruction is common in patients with CF. This is a review of the therapy with bronchodilators, anti-inflammatory agents, mucolytics and mucus modifiers, and airway clearance techniques used to try to overcome the obstruction. It discusses some investigational treatments.
27. Weller PH: Implications of early inflammation and infection in cystic fibrosis: a review of new and potential interventions. Pediatr Pulmonol 1997, 24:143-146. Airway infection and inflammation occur early in CF lung disease. Potential treatments for early intervention in an attempt to delay the progression of the disease are discussed.
28. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC: Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984, 104:352-356.
29. Ramsey BW, Wentz KR, Smith AL: Predictive value of orophary cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991, 144:331-337.
30. Cystic Fibrosis Foundation: National cystic fibrosis patient registry: 1994 Annual Data Report. Bethesda: Cystic Fibrosis Foundation; 1995.
31. Kirschner KK, Wagener JS, Khan TZ, Copenhaxar SC Increased DNA levels in bronchoalveolar with cystic fibrosis. Am J Respir Crit Care Med 1996, 154:1428
32. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, et al.: Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 1997, 131:118-124
33. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al.: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994, 331:637-642.
34. Geller DE: Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease? Pediatr Pulmonol 1997, 24:155-158.
35. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV: A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995, 126:515-523.
36. Konstan MW, Vargo KM, Davis PB: Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
37. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, et al.: Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994, 70:84-89.
38. Valerius NH, Koch C, Hoiby N: Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338:725-726.
39. Frederiksen B, Koch C, Hoiby N: Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23:330-335. Aggressive management of pulmonary exacerbations is crucial in the attempt to maintain pulmonary function. This paper, however, discusses antibiotic treatment when P. aeruginosa is initially cultured from the lungs, which may prevent deterioration of lung function.
40. Frederiksen B, Lanng S, Koch C, Hoiby N: Improved survival in the Danish center treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996, 21:153-158.
41. Dodge JA: Gastrointestinal tract and malnutrition in cystic fibrosis: pathophysiology. J R Soc Med 1986, 79(suppl 12):27-31.
42. Soutter VL, Kristidis P, Gruca MA, Gaskin KJ: Chronic under nutrition/growth retardation in cystic fibrosis. Clin Gastroenterol 1986, 15:137-55.
43. Kraisinger M, Hochhaus G, Stecenko A, Bowess E, Hendeses L: Clinical pharmacology of pancreatic enzymes in patients with cystic fibroris and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994, 34:158-166.